EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Epithelial–mesenchymal transition and cancer-associated fibroblasts in tumor progression and therapy resistance: mechanistic convergence and therapeutic opportunities

Dhiraj Kumar Singh, Rashmi Gupta, Umesh Kumar, Saurabh Gupta

Clinical and Translational Oncology · 11.02.2026 · 28 (8) · 3086-3091

DOI: 10.1007/s12094-026-04255-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, online erschienen am 11.02.2026. Verfasst von Dhiraj Kumar Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of NMR, All India Institute of Medical Sciences Delhi, New Delhi, 110029, India. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Cancer-Associated Fibroblasts, Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer progression and treatment failure are driven not only by tumor-intrinsic alterations but also by dynamic interactions within the tumor microenvironment (TME). Epithelial-mesenchymal transition (EMT) and cancer-associated fibroblasts (CAFs) represent two interlinked mechanisms that promote tumor invasion, metastatic dissemination, stemness, immune evasion, and resistance to therapy. EMT is regulated by transcription factors, such as Snail, ZEB, and Twist, and by signaling pathways including TGF-β, Wnt/β-catenin, and Notch, enabling cancer cells to adopt hybrid epithelial-mesenchymal states that confer phenotypic plasticity and drug tolerance. CAFs, derived from multiple cellular sources, further reinforce EMT programs through paracrine signaling, extracellular matrix remodeling, and metabolic reprogramming. This review critically synthesizes current evidence on EMT-CAF crosstalk in oncogenesis and therapeutic resistance, highlighting emerging clinical strategies, translational challenges, and lessons from failed or limited therapeutic approaches. By emphasizing EMT plasticity and CAF heterogeneity as convergent drivers of tumor adaptability, this work provides a refined framework for developing rational combination therapies targeting both cancer cells and their supportive stroma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionCancer-Associated FibroblastsDrug Resistance, NeoplasmNeoplasmsHumansDisease ProgressionTumor MicroenvironmentAnimalsSignal Transduction

Stichwörter der Autor:innen

CancerCell signalingEMTFibroblastNotchTGF-β1Tumor microenvironmentWnt

Autor:innen und Institutionen

  • Department of NMR, All India Institute of Medical Sciences Delhi, New Delhi, 110029, India.
  • Department of Biochemistry, All India Institute of Medical Sciences Delhi, New Delhi, 110029, India.
  • Chandigarh University, NH5, Chandigarh-Ludhiana Highway, Gharuan, Mohali, Punjab, 140413, India. umeshkumar82@gmail.com.
  • Department of Biotech Engineering, University Institute of Engineering, Chandigarh University, Mohali, Punjab, 140413, India. umeshkumar82@gmail.com.
  • Department of Biotechnology, GLA University, Mathura, Uttar Pradesh, 281406, India.

Zitieren

APA

Singh, D. K., Gupta, R., Kumar, U., & Gupta, S. (2026). Epithelial–mesenchymal transition and cancer-associated fibroblasts in tumor progression and therapy resistance: mechanistic convergence and therapeutic opportunities. Clinical and Translational Oncology, 28(8), 3086-3091. https://doi.org/10.1007/s12094-026-04255-2

Vancouver

Singh DK, Gupta R, Kumar U, Gupta S. Epithelial–mesenchymal transition and cancer-associated fibroblasts in tumor progression and therapy resistance: mechanistic convergence and therapeutic opportunities. Clinical and Translational Oncology. 2026;28(8):3086-3091. doi:10.1007/s12094-026-04255-2

BibTeX
@article{Singh2026,
  author = {Singh, Dhiraj Kumar and Gupta, Rashmi and Kumar, Umesh and Gupta, Saurabh},
  title = {Epithelial–mesenchymal transition and cancer-associated fibroblasts in tumor progression and therapy resistance: mechanistic convergence and therapeutic opportunities},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  volume = {28},
  number = {8},
  pages = {3086--3091},
  doi = {10.1007/s12094-026-04255-2}
}
Kostenlos starten →